Therapeutic-area Dossier
Endocrinology
Therapeutic-area Dossier for Endocrinology (hormone and metabolic medicines). Australian brands, active ingredients, PBS-listed treatments, PBAC outcomes…
- Brand: ACTONEL
- Brand: ACTOS
- Brand: ANDROFORTE
- Brand: APIDRA
- Brand: APO-METFORMIN
- Brand: APX-GLICLAZIDE
- Sponsor: Arrotex Pharmaceuticals
- Sponsor: Novo Nordisk Pharmaceuticals
- Sponsor: Accord Healthcare
- Sponsor: Alphapharm
What is
Endocrinology Endocrinology encompasses the treatment and management of disorders related to hormonal and metabolic function. The therapeutic area includes 323 brands registered in Australia, of which 203 are indexable.
Brands registered in
Endocrinology The top brands registered in Endocrinology are: — ACTOS — ANDROFORTE — APIDRA — APO-DOMPERIDONE — APO-METFORMIN — APX-GLICLAZIDE — APX-METFORMIN — ARDIX — ARX-PIOGLITAZONE — DAONIL — DESMOMED — DESMOPRESSIN ADVZ
Sponsor landscape
The endocrinology therapeutic area has 77 active sponsors. The top sponsors include Arrotex Pharmaceuticals, Accord Healthcare, Alphapharm, Novo Nordisk Pharmaceuticals, Sandoz, Aspen Pharmacare, Pharmacor, and GM Pharma.
PBS and regulatory activity
Fifty-nine brands in endocrinology have PBS-listed items, with the latest PBS schedule dated 1 May 2026. The most recent PBAC outcome in this area is dated 1 November 2025, and the most recent AusPAR is dated 11 August 2025. There are 68 brands with PBAC outcomes on record and 37 brands with AusPARs on record.